Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CTSV | O60911 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703755 | 0.78 | GAA (0.40) | GAAMEN1KMT2A | |
| SCHEMBL13009446 | 0.76 | GAA (0.39) | GAAMEN1KMT2A | |
| SCHEMBL893078 | 0.74 | GAA (0.38) | GAAMEN1KMT2A | |
| SCHEMBL4446863 | 0.74 | GAA (0.38) | GAAMEN1KMT2A | |
| SCHEMBL13008307 | 0.74 | GAA (0.36) | GAAMEN1KMT2A | |
| SCHEMBL13008713 | 0.74 | GAA (0.40) | GAAMEN1KMT2A | |
| SCHEMBL12910935 | 0.73 | GAA (0.37) | GAAMEN1KMT2A | |
| SCHEMBL2814073 | 0.72 | GAA (0.36) | GAAMEN1KMT2A | |
| SCHEMBL40239 | 0.70 | MEN1 (0.39) | GAAMEN1KMT2A | |
| SCHEMBL2810597 | 0.70 | GAA (0.36) | GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8471031-B2 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8471031-B2 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2013-06-25 | — | — | US | disclosed |
| EP-2035381-B1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | BASF SE (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2008003602-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS | CIBA HOLDING INC. (CH) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | PPOX, CBR1, CBR3 | GAA 1862/4885MEN1 4841/4885KMT2A 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.